{ nodes:
[ { id: 0,
       label: 'Azithromycin',
       img: '',
       type: 'inMol',
       totalNbIndications: 21,
       pid: 'P0000197' },
     { id: 1,
       label: 'Intestinal infectious diseases',
       img: './images/redCircle.jpg',
       type: 'indication',
       code: 'A00-A09' },
     { id: 2,
       label: 'Tuberculosis',
       img: './images/redCircle.jpg',
       type: 'indication',
       code: 'A15-A19' },
     { id: 3,
       label: 'Certain zoonotic bacterial diseases',
       img: './images/redCircle.jpg',
       type: 'indication',
       code: 'A20-A28' },
     { id: 4,
       label: 'Other bacterial diseases',
       img: './images/redCircle.jpg',
       type: 'indication',
       code: 'A30-A49' },
     { id: 5,
       label:
        'Infections with a predominantly sexual mode of transmission',
       img: './images/redCircle.jpg',
       type: 'indication',
       code: 'A50-A64' },
     { id: 22,
       label: 'Pertussis',
       img: './images/blueCircle.png',
       type: 'sideEffect',
       occurence: '0.015% - 34%' },
     { id: 23,
       label: 'Acne',
       img: './images/blueCircle.png',
       type: 'sideEffect',
       occurence: '0.06% - 21%' },
     { id: 24,
       label: 'Loose stools',
       img: './images/blueCircle.png',
       type: 'sideEffect',
       occurence: '1.2% - 19.1%' },
     { id: 25,
       label: 'Injection site pain',
       img: './images/blueCircle.png',
       type: 'sideEffect',
       occurence: '6.5%' },
     { id: 26,
       label: 'Application site pain',
       img: './images/blueCircle.png',
       type: 'sideEffect',
       occurence: '6.5%' },
     { id: 191,
       label: 'Azithromycin',
       img: './images/greenCircle.jpg',
       type: 'DDI',
       occurence:
        'The serum concentration of Cisapride can be increased when it is combined with Azithromycin.' },
     { id: 192,
       label: 'Azithromycin',
       img: './images/greenCircle.jpg',
       type: 'DDI',
       occurence:
        'The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Azithromycin is combined with Pimozide.' },
     { id: 193,
       label: 'Azithromycin',
       img: './images/greenCircle.jpg',
       type: 'DDI',
       occurence:
        'The serum concentration of Terfenadine can be increased when it is combined with Azithromycin.' },
     { id: 194,
       label: 'Azithromycin',
       img: './images/greenCircle.jpg',
       type: 'DDI',
       occurence:
        'The risk or severity of myopathy and rhabdomyolysis can be increased when Azithromycin is combined with Atorvastatin.' },
     { id: 195,
       label: 'Azithromycin',
       img: './images/greenCircle.jpg',
       type: 'DDI',
       occurence:
        'The serum concentration of Acetyldigitoxin can be increased when it is combined with Azithromycin.' },
     { id: 1368,
       label: 'TSHR',
       img: './images/orangeCircle.jpg',
       type: 'interactions',
       uniprot_id: 'P16473',
       uniprot_name: 'TSHR_HUMAN',
       activity_reg: '' },
     { id: 1369,
       label: 'CYP3A4',
       img: './images/orangeCircle.jpg',
       type: 'interactions',
       uniprot_id: 'P08684',
       uniprot_name: 'CP3A4_HUMAN',
       activity_reg: '' },
     { id: 1370,
       label: 'PTGS1',
       img: './images/orangeCircle.jpg',
       type: 'interactions',
       uniprot_id: 'P23219',
       uniprot_name: 'PGH1_HUMAN',
       activity_reg: '' },
     { id: 1371,
       label: 'PTGS2',
       img: './images/orangeCircle.jpg',
       type: 'interactions',
       uniprot_id: 'P35354',
       uniprot_name: 'PGH2_HUMAN',
       activity_reg:
        'ACTIVITY REGULATION: Inhibited by nonsteroidal anti-inflammatory drugs (NSAIDs) including aspirin, ibuprofen, flurbiprofen and celecoxib (PubMed:26859324). Inhibited by flufenamic acid, mefenamic acid and tolfenamic acid (PubMed:27226593). {ECO:0000269|PubMed:26859324, ECO:0000269|PubMed:27226593}.' },
     { id: 1372,
       label: 'PADI4',
       img: './images/orangeCircle.jpg',
       type: 'interactions',
       uniprot_id: 'Q9UM07',
       uniprot_name: 'PADI4_HUMAN',
       activity_reg:
        'ACTIVITY REGULATION: Strongly Inhibited by F-amidine and N-alpha-benzoyl-N5-(2-chloro-1-iminoethyl)-L-ornithine amide (Cl-amidine). These inhibitors are however not specific to PADI4 and also inhibit other members of the family (PubMed:17002273). Incorporation of a carboxylate ortho to the backbone amide of Cl-amidine results in inhibitors with increased specificity for PADI4: N-alpha-(2-carboxyl)benzoyl-N(5)-(2-fluoro-1-iminoethyl)-L-ornithine amide (o-F-amidine) and N-alpha-(2-carboxyl)benzoyl-N(5)-(2-chloro-1-iminoethyl)-L-ornithine amide (o-Cl-amidine) (PubMed:21882827). Strongly and specifically inhibited by Thr-Asp-F-amidine (TDFA); other members of the family are not inhibited (PubMed:22004374). {ECO:0000269|PubMed:17002273, ECO:0000269|PubMed:21882827, ECO:0000269|PubMed:22004374}.' } ],
  links:
   [ { source: 0,
       target: 1,
       value: '',
       coauthors: 'Azithromycin and Intestinal infectious diseases' },
     { source: 0,
       target: 2,
       value: '',
       coauthors: 'Azithromycin and Tuberculosis' },
     { source: 0,
       target: 3,
       value: '',
       coauthors: 'Azithromycin and Certain zoonotic bacterial diseases' },
     { source: 0,
       target: 4,
       value: '',
       coauthors: 'Azithromycin and Other bacterial diseases' },
     { source: 0,
       target: 5,
       value: '',
       coauthors:
        'Azithromycin and Infections with a predominantly sexual mode of transmission' },
     { source: 0,
       target: 22,
       value: '',
       coauthors: 'Azithromycin and Pertussis' },
     { source: 0,
       target: 23,
       value: '',
       coauthors: 'Azithromycin and Acne' },
     { source: 0,
       target: 24,
       value: '',
       coauthors: 'Azithromycin and Loose stools' },
     { source: 0,
       target: 25,
       value: '',
       coauthors: 'Azithromycin and Injection site pain' },
     { source: 0,
       target: 26,
       value: '',
       coauthors: 'Azithromycin and Application site pain' },
     { source: 0,
       target: 191,
       value: '',
       coauthors: 'Azithromycin and Azithromycin' },
     { source: 0,
       target: 192,
       value: '',
       coauthors: 'Azithromycin and Azithromycin' },
     { source: 0,
       target: 193,
       value: '',
       coauthors: 'Azithromycin and Azithromycin' },
     { source: 0,
       target: 194,
       value: '',
       coauthors: 'Azithromycin and Azithromycin' },
     { source: 0,
       target: 195,
       value: '',
       coauthors: 'Azithromycin and Azithromycin' },
     { source: 0,
       target: 1368,
       value: '',
       coauthors: 'Azithromycin and TSHR' },
     { source: 0,
       target: 1369,
       value: '',
       coauthors: 'Azithromycin and CYP3A4' },
     { source: 0,
       target: 1370,
       value: '',
       coauthors: 'Azithromycin and PTGS1' },
     { source: 0,
       target: 1371,
       value: '',
       coauthors: 'Azithromycin and PTGS2' },
     { source: 0,
       target: 1372,
       value: '',
       coauthors: 'Azithromycin and PADI4' } ] }
